RU2543720C2 - Композиции для лечения воспаления и способы лечения воспаления - Google Patents

Композиции для лечения воспаления и способы лечения воспаления Download PDF

Info

Publication number
RU2543720C2
RU2543720C2 RU2011146005/04A RU2011146005A RU2543720C2 RU 2543720 C2 RU2543720 C2 RU 2543720C2 RU 2011146005/04 A RU2011146005/04 A RU 2011146005/04A RU 2011146005 A RU2011146005 A RU 2011146005A RU 2543720 C2 RU2543720 C2 RU 2543720C2
Authority
RU
Russia
Prior art keywords
present
alkyl
compound
certain embodiments
compounds
Prior art date
Application number
RU2011146005/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2011146005A (ru
Inventor
Пер ГЬЕРСТРУП
С. Эрик ШВАРЦ
Original Assignee
С.Т. Ризолв Сарл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by С.Т. Ризолв Сарл filed Critical С.Т. Ризолв Сарл
Publication of RU2011146005A publication Critical patent/RU2011146005A/ru
Application granted granted Critical
Publication of RU2543720C2 publication Critical patent/RU2543720C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
RU2011146005/04A 2009-04-13 2010-04-13 Композиции для лечения воспаления и способы лечения воспаления RU2543720C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16873909P 2009-04-13 2009-04-13
US61/168,739 2009-04-13
US17480609P 2009-05-01 2009-05-01
US61/174,806 2009-05-01
PCT/US2010/030813 WO2010120719A1 (en) 2009-04-13 2010-04-13 Compositions and methods for the treatment of inflammation

Publications (2)

Publication Number Publication Date
RU2011146005A RU2011146005A (ru) 2013-05-20
RU2543720C2 true RU2543720C2 (ru) 2015-03-10

Family

ID=42982804

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011146005/04A RU2543720C2 (ru) 2009-04-13 2010-04-13 Композиции для лечения воспаления и способы лечения воспаления

Country Status (15)

Country Link
US (2) US8673881B2 (https=)
EP (1) EP2419399B1 (https=)
JP (1) JP5785537B2 (https=)
CN (1) CN104203901A (https=)
AU (1) AU2010236663B2 (https=)
BR (1) BRPI1011325A2 (https=)
CA (1) CA2758586A1 (https=)
CL (1) CL2011002548A1 (https=)
ES (1) ES2576086T3 (https=)
IL (1) IL215592A (https=)
MX (1) MX2011010827A (https=)
NZ (1) NZ596228A (https=)
RU (1) RU2543720C2 (https=)
TW (1) TW201039815A (https=)
WO (1) WO2010120719A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US8900626B2 (en) * 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
RU2497498C2 (ru) * 2012-02-14 2013-11-10 Константин Николаевич Руссков Фармацевтическая композиция для профилактики пролиферативной клеточной реакции "митомицин-о"
WO2014030132A2 (en) 2012-08-22 2014-02-27 Universidad De Los Andes Use of statins for periodontal disease and bone regeneration
WO2014063105A1 (en) * 2012-10-19 2014-04-24 Celus Pharmaceuticals, Inc. Vitamin d analogues for the treatment of a neurological disorder
HK1219654A1 (zh) 2013-02-22 2017-04-13 University Of Southern California 用於治疗眼科疾病和病症的方法
WO2016028800A1 (en) * 2014-08-20 2016-02-25 A.T. Resolve Sarl Treatment of corneal haze
WO2016144569A1 (en) 2015-03-10 2016-09-15 Elc Management Llc Methods and compositions for treating skin to resolve inflammation and screening for actives that stimulate pro-resolution pathways
CN105287480B (zh) * 2015-10-28 2019-01-11 西安医学院第一附属医院 Resolvin D1作为抗癫痫药物的应用
WO2018002930A1 (en) 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
EP3624815A4 (en) * 2017-05-15 2021-01-20 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS
CN107445821A (zh) * 2017-08-11 2017-12-08 上海中医药大学 聚炔酸类衍生物
CN112955145A (zh) 2018-09-04 2021-06-11 密涅瓦神经科学有限公司 使用苯氧丙胺化合物治疗疼痛的方法
AU2019463156B2 (en) * 2019-08-27 2024-08-15 Cellin Technologies Oü Activated mesenchymal stem cells for treating limb ischemia
JP2023504205A (ja) * 2019-12-09 2023-02-01 ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ 角膜病変の治療のための生体分子
CN110988180A (zh) * 2019-12-19 2020-04-10 山东达因海洋生物制药股份有限公司 一种基于杂质谱的埃索美拉唑镁的有关物质分析方法
WO2023250031A1 (en) * 2022-06-21 2023-12-28 Anida Pharma Inc. Compositions and methods for treating hearing and ocular disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050228047A1 (en) * 2002-04-01 2005-10-13 Petasis Nicos A Trihydroxy polyunsaturated eicosanoid derivatives
RU2004117546A (ru) * 2001-11-06 2006-01-10 Шеринг Акциенгезельшафт (De) Аналоги липоксина а4
WO2009038671A2 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for treating autoimmune diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
AU2002349297A1 (en) 2001-12-03 2003-06-17 Kobenhavns Amt Statin-like compounds
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
DE102008027146B4 (de) 2008-06-02 2012-01-19 Ing. Erich Pfeiffer Gmbh Austragvorrichtung
WO2010039531A1 (en) * 2008-09-23 2010-04-08 Resolvyx Pharmaceuticals, Inc. Therapeutic compounds
US8619544B2 (en) 2008-09-23 2013-12-31 Qualcomm Incorporated Apparatus and method for facilitating transmit diversity for communications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004117546A (ru) * 2001-11-06 2006-01-10 Шеринг Акциенгезельшафт (De) Аналоги липоксина а4
US20050228047A1 (en) * 2002-04-01 2005-10-13 Petasis Nicos A Trihydroxy polyunsaturated eicosanoid derivatives
WO2009038671A2 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for treating autoimmune diseases

Also Published As

Publication number Publication date
EP2419399A4 (en) 2012-08-29
US8673881B2 (en) 2014-03-18
CL2011002548A1 (es) 2012-07-20
MX2011010827A (es) 2012-01-20
CA2758586A1 (en) 2010-10-21
BRPI1011325A2 (pt) 2016-03-15
AU2010236663B2 (en) 2015-08-20
IL215592A0 (en) 2011-12-29
EP2419399B1 (en) 2016-03-23
US20120101061A1 (en) 2012-04-26
US9315447B2 (en) 2016-04-19
IL215592A (en) 2017-02-28
CN104203901A (zh) 2014-12-10
JP5785537B2 (ja) 2015-09-30
AU2010236663A1 (en) 2011-11-24
WO2010120719A1 (en) 2010-10-21
NZ596228A (en) 2014-01-31
US20140275247A1 (en) 2014-09-18
JP2012523459A (ja) 2012-10-04
TW201039815A (en) 2010-11-16
ES2576086T3 (es) 2016-07-05
HK1166305A1 (zh) 2012-10-26
EP2419399A1 (en) 2012-02-22
RU2011146005A (ru) 2013-05-20

Similar Documents

Publication Publication Date Title
RU2543720C2 (ru) Композиции для лечения воспаления и способы лечения воспаления
CN105017187A (zh) 用于治疗皮肤病症或疾病状态的tofa类似物
CN109640967B (zh) 抑制胆碱向三甲胺(tma)的转化的方法
CN103191129A (zh) 治疗眼睛病症的脂氧化物类化合物
WO2010039531A1 (en) Therapeutic compounds
JP2016514702A (ja) アンギオテンシン関連疾患の処置のための方法、化合物および組成物
JP2010265322A (ja) 肝細胞増殖因子（分散因子）活性のピラゾール誘導体モジュレーター
JP7368516B2 (ja) ｓＧＣ刺激剤のリンプロドラッグ
JP6068457B2 (ja) 化合物及び組成物
KR101732751B1 (ko) Ｒｅｌ-ｎ-［6-［(2ｒ,6ｓ)-2,6-디메틸-4-모르폴리닐］-3-피리디닐］-2-메틸-4'-(트리플루오로메톡시)-［1,1'-비페닐］-3-카르복스아미드를 포함한 국소 제약 조성물
US20060084695A1 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
CN101821227A (zh) 激素敏感性脂酶调节剂及使用方法
EP3639855A1 (en) Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
TWI537245B (zh) 用於治療自體免疫發炎疾病之化合物
US20110245528A1 (en) Therapeutic compounds
EP1017385B1 (fr) Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta1
KR100372562B1 (ko) 류코트리엔 생성 저해활성을 가지는 정유 성분
HK1166305B (en) Compositions and methods for the treatment of inflammation
AU2002363318B2 (en) Compounds and methods for treating transplant rejection
US20240217952A1 (en) Treatment of graft-versus-host disease with inhibitors of bet family bdii bromodomain
JP5792318B2 (ja) ブロムフェナク有機塩、ならびにその製造方法、組成物および使用
EP1596845A1 (fr) Utilisation therapeutique de glycerols acyles et de leurs analogues azotes et sulfures
TW202509038A (zh) 異穿心蓮內酯（ｉｓｏａｎｄｒｏｇｒａｐｈｏｌｉｄｅ）類似物及使用其之治療方法
HK40110140A (zh) 一类具有萘胺结构的小分子化合物的用途
JP2013028535A (ja) 分化誘導因子又はその類縁体を含有する抗炎症剤

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170414